Form 4: CareDx CEO Trades Shares Under 10b5-1 Plan

CareDx, Inc. President and CEO John Walter Hanna Jr. reported a series of stock transactions, including acquisitions and sales, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• John Walter Hanna Jr., President and CEO of CareDx, Inc., engaged in multiple stock transactions between June 4, 2026, and June 29, 2026.
• These transactions involved the acquisition of common stock at a price of $8.20 per share, totaling 706 shares on June 4, 2026, and increasing to 701,859 shares by June 29, 2026.
• Concurrently, sales of common stock occurred at a weighted average price ranging from $29.00 to $29.58 per share.
• Specifically, 100 shares were sold on June 26, 2026, and 39,900 shares were sold on June 29, 2026.
• All sales were conducted under a Rule 10b5-1 trading plan adopted on December 12, 2025, which is designed to comply with affirmative defense conditions.
• The reporting person also holds employee stock options with an exercise price of $8.20, with vesting schedules detailed in the filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive stock transactions under a pre-defined plan, providing transparency without immediate positive or negative indicators for the company's performance.

Positives

• The CEO's stock transactions were executed under a Rule 10b5-1 plan, indicating adherence to pre-planned trading strategies designed to avoid insider trading concerns.
• The acquisition of shares at $8.20 per share suggests a potential belief in the company's undervaluation or a commitment to increasing personal holdings at that price point.
• The CEO continues to hold a significant number of shares and options, indicating ongoing beneficial ownership and alignment with shareholder interests.

Negatives

• The sale of shares at prices significantly higher than the acquisition price ($29.00-$29.58 vs. $8.20) could be interpreted by some investors as the CEO taking profits, although this is standard under a 10b5-1 plan.
• The filing details multiple transactions, which, while planned, can create noise and potential for misinterpretation in the market regarding insider sentiment.

Risks

• The Rule 10b5-1 plan itself is subject to market conditions and the company's performance, which could impact the execution and outcomes of future trades.
• While the plan is designed to mitigate insider trading concerns, significant sales by a CEO can still be perceived negatively by the market, potentially impacting share price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future financial performance. It solely reports on past transactions by an executive.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 12, 2025.
• The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.58 per share, inclusive.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• 1/4th of the shares subject to the option shall vest on April 15, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive stock transactions are common in the biotechnology and diagnostics sector, where stock-based compensation and insider trading regulations are closely monitored. The use of Rule 10b5-1 plans is a standard practice for executives to manage their holdings transparently.

Stakeholder Impact

• Shareholders: The transactions provide transparency into executive stock activity, which can influence investor perception. The sales at higher prices may be seen as profit-taking, while acquisitions at lower prices could signal confidence.
• Employees: The details on stock option vesting may be of interest to employees who also hold options or stock.
• Management: The CEO's adherence to a Rule 10b5-1 plan demonstrates compliance with corporate governance and insider trading policies.

Next Steps

• Continued execution of the Rule 10b5-1 trading plan as per its terms.
• Potential future filings of Form 4 to report further changes in beneficial ownership.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Options, Beneficial Ownership, CareDx, CDNA, Executive Transactions, Stock Sales, Stock Acquisitions